Canaccord Genuity Reiterates a 'Hold' on Momenta Pharmaceuticals (MNTA); Q2: First Clarity on Baxter (BAX) Biosimilars Deal
Tweet Send to a FriendGet Alerts MNTA Hot Sheet
Price: $13.39 +0.60%
Rating Summary:
3 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
3 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade MNTA Now!
Canaccord Genuity reiterates a 'Hold' on Momenta Pharmaceuticals (NASDAQ: MNTA) price target of $12.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on lack of near--term catalysts but long--term biosimilars potential remains. M-enox revenues are now a modest royalty stream, and M356 generic Copaxone launch is delayed until 2016. While MNTA's Baxter-partnered (NYSE: BAX) biosimilars program and branded drugs have significant long-term potential, lack of near-term catalysts likely limits 12- month upside."
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $14.12 yesterday, with a 52 week range of $10.15-$19.64.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Ritu Baral, said, "Reiterate rating and price target on lack of near--term catalysts but long--term biosimilars potential remains. M-enox revenues are now a modest royalty stream, and M356 generic Copaxone launch is delayed until 2016. While MNTA's Baxter-partnered (NYSE: BAX) biosimilars program and branded drugs have significant long-term potential, lack of near-term catalysts likely limits 12- month upside."
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $14.12 yesterday, with a 52 week range of $10.15-$19.64.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Needham & Company Lifts Numbers on Marvell (MRVL) on Solid Results
- Needham & Company Boosts Numbers on Infoblox (BLOX) on Strong Q3
- Janney Capital Boosts PT on Gap (GPS) Post Q1
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
